Back to top
more

Insulet Corporation (PODD)

(Delayed Data from NSDQ)

$262.67 USD

262.67
476,015

+0.31 (0.12%)

Updated Feb 25, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum C VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (159 out of 253)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Insulet (PODD) Q4 Earnings Fall Shy of Estimates, Revenues Beat

Insulet's (PODD) Q4 revenues were significantly boosted by the robust adoption of Omnipod DASH and a growing customer base.

Insulet (PODD) Omnipod DASH Reaches Canada, Global Hold Widens

Insulet's (PODD) Omnipod DASH system provides 72 hours of continuous insulin therapy, simplifying lives with no more daily injection.

Insulet (PODD) Down 0.1% Since Last Earnings Report: Can It Rebound?

Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Insulet (PODD) Q3 Earnings & Revenues Top Estimates, View Up

Insulet's (PODD) Q3 gross margin improvement can be primarily attributed to performance of the company's U.S. manufacturing and favorable revenue mix from the shift to higher volume

Insulet (PODD) Beats Q3 Earnings and Revenue Estimates

Insulet (PODD) delivered earnings and revenue surprises of 183.33% and 5.81%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Insulet (PODD) Q3 Earnings Expected to Decline

Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DexCom (DXCM) Q3 Earnings and Revenues Surpass Estimates

DexCom's (DXCM) third-quarter results benefit from solid segmental performance.

Masimo (MASI) Earnings and Revenues Beat Estimates in Q3

Masimo (MASI) continues to gain from key Product segment, which witnessed solid growth in Q3.

Varian (VAR) Earnings and Revenues Surpass Estimates in Q4

Varian's (VAR) receipt of 10 Ethos orders in Q4 instills optimism

LabCorp (LH) Q3 Earnings Beat Estimates, Margins Expand

LabCorp (LH) Diagnostics business in Q3 grows significantly on organic volume improvements as a result of growing demand for COVID-19 testing.

Ecolab (ECL) Earnings and Revenues Surpass Estimates in Q3

Although Ecolab's (ECL) third-quarter results reflect weakness in the Global Industrial and Institutional segments, its Global Healthcare and Life Sciences unit shows strength.

NextGen Healthcare (NXGN) Gains 8.1% Post Q2 Earnings Beat

NextGen (NXGN) benefited from both its operating segments in Q2.

Quest Diagnostics' (DGX) Q3 Earnings Beat, Base Volume Rises

In Q3, Quest Diagnostics (DGX) sees strong signs of the health care system returning to pre-pandemic levels

Align Technology (ALGN) Beats on Q3 Earnings, Margins Up

Align Technology's (ALGN) segments report solid rebound in sales across geographies despite the pandemic-led business challenges.

Edwards Lifesciences (EW) Beats on Q3 Earnings, Margins Up

Despite coronavirus-led business challenges, Edwards Lifesciences (EW) witnessed steady improvement in TAVR procedure volumes in Q3.

Abbott (ABT) Q3 Earnings Top, Diagnostic Test Sales Solid

In Q3, Abbott (ABT) registers solid worldwide adoption of FreeStyle Libre System.

Thermo Fisher (TMO) Q3 Earnings Beat on Life Sciences Sales

Significant COVID-19 led business expansions, as well as Thermo Fisher's (TMO) base business growth contribute to a stunning Q3 performance.

The Zacks Analyst Blog Highlights: Zoom Video, Entegris, Copart, Insulet and Intuit

The Zacks Analyst Blog Highlights: Zoom Video, Entegris, Copart, Insulet and Intuit

HEXO in Focus: Stock Moves 5.2% Higher

HEXO saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Nalak Das headshot

Nasdaq Set to Outperform 2019 on Digitization Push: 5 Picks

This year, the technology sector is leading the V-shaped recovery from the unprecedented health-hazard-led economic devastation.

Abbott's Libre 3 Receives CE Mark, Boosts CGM Prospects

Abbott's (ABT) environment-friendly next-generation FreeStyle Libre 3 system aims to provide a better quality of life to diabetics in Europe at the same affordable price of previous systems.

Insulet (PODD) Hits a New 52-Week High: What's Driving It?

Insulet (PODD) is optimistic about maintaining growth momentum of its Omnipod system along with tapping the booming diabetes market.

Debanjana Dey headshot

4 Best Diabetes Device Stocks to Focus on Amid Coronavirus Crisis

Here are a few diabetes-centric MedTech stocks that investors can focus on to reap profits amid the pandemic-battered stock market situation.

Insulet's Omnipod DASH Shines, New Omnipod Uptake Slows Down

Insulet (PODD) adds significant capacity in preparation of the Omnipod 5 launch in 2021.

Why Is Insulet (PODD) Down 7.1% Since Last Earnings Report?

Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.